ASCO 2020 HCC In Depth

ASCO 2020 HCC In-Depth

Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers

A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.

Comparing Stereotactic Body Radiation Therapy With Transarterial Chemoembolization in Early-Stage HCC

SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.

Lenvatinib, Pembrolizumab Combination Promising in Unresectable HCC

The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.

Apatinib Significantly Improved Survival in Chinese Patients with Advanced HCC

The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.

Circulating Tumor DNA Levels Linked with Tumor Burden, Survival in HCC

Noninvasive method could help monitor treatment responses.

Intrahepatic T-VEC Injection Plus Pembrolizumab Feasible in HCC, Liver Metastases

Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.